Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia.

Nosocomial pneumonia carries a high morbidity and mortality and creates a large burden on health care use. As resistance to currently available antibiotics continues to increase, the role of pharmacodynamics in drug regimen optimization becomes pivotal to the clinical success of patient therapy. This article reviews the evidence behind pharmacodynamic optimization including the use of Monte Carlo simulations, changes in pharmacokinetic parameters of critically ill patients, and differing strategies to optimize drug regimens. Emphasis is placed on drugs used to treat hospital-acquired and ventilator-acquired pneumonia, and programs implementing pharmacodynamic optimization are highlighted.
AuthorsSeth T Housman, Joseph L Kuti, David P Nicolau
JournalClinics in chest medicine (Clin Chest Med) Vol. 32 Issue 3 Pg. 439-50 (Sep 2011) ISSN: 1557-8216 [Electronic] United States
PMID21867814 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2011 Elsevier Inc. All rights reserved.
Chemical References
  • Anti-Bacterial Agents
  • Anti-Bacterial Agents (administration & dosage, pharmacokinetics)
  • Humans
  • Monte Carlo Method
  • Pneumonia, Bacterial (drug therapy)
  • Pneumonia, Ventilator-Associated (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: